港股異動丨創新藥繼續受資金追捧,三生製藥、康方生物、科倫博泰生物均超創歷史新高
隔夜美股市場創新藥股強勢,帶動港股市場創新藥概念股今日繼續活躍。其中,康方生物升超10%再創歷史新高,三生製藥升超8%再創歷史新高,科倫博泰生物升超7%再創歷史新高,樂普生物、康諾亞、百濟神州、亞盛醫藥、中國生物製藥等跟升。消息面上,中國生物製藥公佈以5.01億美元收購禮新醫藥(LaNova)剩餘95.09%股權。花旗發表報吿指,中國生物製藥收購禮新醫藥將進一步擴展中生製藥創新產品線。這宗交易也是中國製藥業的一個里程碑。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.